Interferon-α2b therapy in low-activity hepatitis C: A pilot study

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 12, 1997, Pages 1256-1260

  Nordoy I ^a   Krarup, H B ^b   Bell, H ^b   Christensen, P B ^b   Elgjo, K ^b   Von Der Lippe, B ^b   Schaffalitzky De Muckadell, O ^b   Maeland A ^b   Ring Larsen, H ^b   Samdal, H H ^b   Simmonds, P ^b   Skaug, K ^b   Tage Jensen, U ^b   Schrumpf, E ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Alanine aminotransferase levels; Chronic hepatitis C; Genotype; Interferon; Normal

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GENOTYPE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 14444281160     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529709028156     Document Type: Article

References (36)

1. Chamaya K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040-3.
2. Varagona G, Brown D, Kibbler H, Scheuer P, Ashrafzadeh P, Sherlock S, et al. Respone, relapse and retreatment rates and viremia in chronic hepatitis C treated with α2b interferon. A phase III study. Eur J Gastroenterol Hepatol 1992;4:707-12.
3. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993;104:877-83.
4. Douglas DD, Rakela J, Lin HJ, Hollinger FB, Taswell HF, Czaja AJ, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV-RNA and anti-HCV IgM. Dig Dis Sci 1993;38:601-7.
5. Chemello L, Cavaletto L, Noventa F, Bonetti P, Casarin C, Bernardinello E, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C with interferon-α. J Viral Hepatitis 1995;2:91-6.
6. Tsubita A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C infection. Hepatology 1994;19:1088-94.
7. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
8. Booth JCL, Brown JL, Thomas HC. The managment of chronic hepatitis C virus infection. Gut 1995;37:449-54.
9. Esteban JI, Lopez-Talvera JC, Genesca J, Madoz P, Viladomiu L, Muniz E, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-9.
10. Alberti A, Morsica G, Chemello L, Cavaletto D, Noventa F, Pontisso P, et al. Hepatitis C viremia and liver in symptom-free individuals with anti-HCV. Lancet 1992;340:697-8.
11. Nordøy I, Schrumpf E, Elgjo K, Flesland Ø, Andersen Glende J, Ørjasæter H, et al. Liver disease in anti-hepatitis C virus-positive Norwegian blood donors. Scand J Gatroenterol 1994; 29:77-81.
12. Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kasahara A, Fusamoto H, et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994;19:871-5.
13. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
14. van Thiel DH, Caraceno P, Molloy PJ, Hassanein T, Kania RJ, Gurakar A, et al. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon α2b therapy. J Hepatol 1995;23:503-8.
15. Serfaty L, Chazouillères O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistenly normal aminotransferase activity. Gastroenterology 1996;110:291-5.
16. Ideo G, Bellobuono A. Tempini S, Bellati G, Romano L, Zanetti AR. Interferon treatment of chronic hepatitis C patients with normal or near normal alanine-amino-tranferase levels: might it be harmful rather than useful? Int Hepatol Comm 1996;6:8-15.
17. Sangiovanni A, Spinzi GC, Ceriani R, Prada A, Bissoli F, Morales R, et al. Randomized controlled trial of HCV healthy carriers treatment with interferon (IFN) [abstract]. Hepatology 1995;22(4 Suppl):290A.
18. Salmerón J, Pèrez-Ruiz M, Palacios A, Caballero T, Torres C, Bellot V, et al. Interferon (IFN) alpha treatment of chronic hepatitis C (CHC) with normal vs elevated alanine aminotransferase (ALT) levels [abstract]. J Hepatol 1995;23 Suppl 1:105.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
20. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-102.
21. Garson JA, Ring CJA, Tuke PW. Improvement of HCV genome detection with 'short' PCR products. Lancet 1991;338:1466-7.
22. Bjøro K, Frøland SS, Yun Z, Samdal HH, Haaland T. HCV infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globuline. N Eng J Med 1994;331:1607-11.
23. Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC, Follett AC. et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 1995;76:1197-204.
24. Review by an International Group. Acute and chronic hepatitis revisited. Lancet 1977;2:914-9.
25. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992;15:567-71.
26. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic active hepatitis: a comparative analysis. Hepatology 1992;15:572-7.
27. Hagiwara H, Hayashi N, Kasahara A, Oshita M, Katayama K, Kato M, et al. Treatment with recombinant interferon α2a for patients with chronic hepatitis C: predictive factors for biochemical and virologic response. Scand J Gastroenterol 1996; 31:1021-6.
28. Tsubota A, Kumasa H, Chayama K, Arase Y, Saitoh S, Koida I, et al. Relationship between pretreatment viremia level and response to interferon-a therapy in chronic hepatitis C differs in viral type 1 and 2 infection. Dig Dis Sci 1996;41:1925-32.
29. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.
30. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Hoh Y, Takayanagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293-9.
31. Takada N, Takase S, Enomoto N, Takada A, Date T. Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 1992;14:35-40.
32. Chemello L. Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med 1994; 330:143.
33. Brechot C. Hepatitis C virus genetic variability: clinical implications. Am J Gastroenterol 1994;89:S41-7.
34. Young KKY, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by a combined transcription polymerase chain reaction assay. Clin Microbiol 1993;31:882-6.
35. Bell H, Helium K, Hartug S, Mæland A, Ritland S, Myrvang B, et al. Prevalence of hepatitis C genotypes among patients with chronic hepatitis C in Norway. Scand J Infect Dis 1996;28:357-9.
36. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.